Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.
Adenoviridae
/ immunology
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
B-Lymphocytes
/ immunology
COVID-19
/ immunology
COVID-19 Vaccines
/ immunology
Female
Immunogenicity, Vaccine
/ immunology
Immunologic Memory
/ immunology
Macaca mulatta
Male
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Vaccination
/ methods
Viral Vaccines
/ immunology
Ad26.COV2.S
COVID-19
SARS-CoV-2
humoral immunity
immunology
memory B cells
non-human primates
protection
vaccination
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
24 06 2021
24 06 2021
Historique:
received:
02
02
2021
revised:
18
03
2021
accepted:
25
05
2021
pubmed:
17
6
2021
medline:
2
7
2021
entrez:
16
6
2021
Statut:
ppublish
Résumé
We previously reported that a single immunization with an adenovirus serotype 26 (Ad26)-vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) protected rhesus macaques against SARS-CoV-2 challenge. To evaluate reduced doses of Ad26.COV2.S, 30 rhesus macaques were immunized once with 1 × 10
Identifiants
pubmed: 34133941
pii: S0092-8674(21)00693-0
doi: 10.1016/j.cell.2021.05.040
pmc: PMC8166510
mid: NIHMS1710150
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3467-3473.e11Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI124377
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA260476
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI129797
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI135098
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126603
Pays : United States
Organisme : NIH HHS
ID : R01 OD024917
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests D.H.B., R.Z., F.W., and H.S are co-inventors on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). R.Z., F.W., S.R.H., M.v.H., L.v.d.F., and H.S. are employees of Janssen Vaccines & Prevention BV and may hold stock in Johnson & Johnson.
Références
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Sci Transl Med. 2018 Feb 14;10(428):
pubmed: 29444980
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
J Clin Invest. 2010 Nov;120(11):3878-90
pubmed: 20972331
Nature. 2004 Apr 1;428(6982):561-4
pubmed: 15024391
J Leukoc Biol. 2015 Jan;97(1):19-30
pubmed: 25341725
J Virol. 2021 Mar 16;:
pubmed: 33727331
J Virol. 2007 May;81(9):4654-63
pubmed: 17329340
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Cell. 2020 Aug 6;182(3):713-721.e9
pubmed: 32778225
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Nat Med. 2020 Nov;26(11):1694-1700
pubmed: 32884153
NPJ Vaccines. 2020 Sep 28;5:91
pubmed: 33083026
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946